Paul Hansen Biography and Net Worth

Director of Vyant Bio

Mr. Hansen has been a member of the Board of Directors of StemoniX since 2015. Since 2014, Mr. Hansen has served as a Senior Fellow with the University of Minnesota’s Technological Leadership Institute. Mr. Hansen is a founder and, since 2016, has been President of Minnepura Technologies, SBC. From 1999 to 2014, Mr. Hansen held senior executive positions at 3M Company, including President and CEO of 3M Mexico. Mr. Hansen holds a BA in Chemistry and Economics from St. Olaf College and an MBA in Marketing Management from the Carlson School of Management at the University of Minnesota.

How do I contact Paul R. Hansen?: The corporate mailing address for Mr. Hansen and other Vyant Bio executives is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. Vyant Bio can also be reached via phone at (201) 479-1357 and via email at [email protected]. Learn More on Paul R. Hansen's contact information.
Has Paul R. Hansen been buying or selling shares of Vyant Bio?: Paul R. Hansen has not been actively trading shares of Vyant Bio during the last ninety days. Most recently, on Thursday, August 19th, Paul R. Hansen bought 20,000 shares of Vyant Bio stock. The stock was acquired at an average cost of $2.35 per share, with a total value of $47,000.00. Learn More on Paul R. Hansen's trading history.
Who are Vyant Bio's active insiders?: Vyant Bio's insider roster includes Marcus Boehm (Director), R. Fletcher (Director), Paul Hansen (Director), John Roberts (CEO), and Yung-Ping Yeh (Insider). Learn More on Vyant Bio's active insiders.

Paul R. Hansen Insider Trading History at Vyant Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/19/2021	Buy	20,000	$2.35	$47,000.00

Paul R. Hansen Buying and Selling Activity at Vyant Bio

Vyant Bio Company Overview

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

Today's Range

Now: $0.19

$0.18

$0.20

50 Day Range

MA: $0.19

$0.19

2 Week Range

Now: $0.19

$0.14

$1.58

Volume

19,100 shs

Average Volume

161,822 shs

Market Capitalization

$1.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.